7 February 2017 - Perrigo announced that it has filed an abbreviated new drug application with the U.S. FDA for clindamycin, benzoyl peroxide topical gel, the generic version of Onexton gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). 

Perrigo has notified Valeant Pharmaceuticals and Dow Pharmaceutical Sciences (Valeant) the owner of both the new drug application and patents listed in FDA's Orange Book, of its filing.

Read Perrigo press release